touchIME is the education division of touchONCOLOGY, we pride ourselves on providing innovative independent learning activities for busy healthcare professionals.
Watch the footage from our Satellite Symposium at ESMO-IO 2018, with internationally renowned expert faculty discussing the role of immunotherapy in the rapidly evolving treatment paradigm for NSCLC without an oncogenic driver mutation.
Watch a panel of internationally renowned experts discuss the factors influencing the choice of first-line treatment for patients with advanced soft tissue sarcoma and the interpretation of data from clinical trials in this patient population.
Watch internationally renowned expert, Professor Stephen Johnston, discuss key data in advanced breast cancer presented at the San Antonio Breast Cancer Symposium (SABCS) 2018 Congress, 3–8 December 2018.
Watch leading breast cancer clinicians from Europe and Japan discuss the latest data from the San Antonio Breast Cancer Symposium (SABCS) 2018 Congress, 3-8 December 2018, and what they mean for global and regional clinical practice.
Watch internationally renowned expert, Dr Javier Cortés, discuss key data in advanced breast cancer presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany.
Watch leading breast cancer clinicians from Europe and Japan discuss the latest data from the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, and what they may mean for global and regional clinical practice.
Watch a group of leading breast cancer specialists debate and discuss how to optimize clinical outcomes for patients with advanced HR+/HER2- disease in the era of CDK4/6 inhibition.
Watch internationally renowned breast cancer expert, Professor Nadia Harbeck, discuss key data in advanced breast cancer presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA.
Dr. Andrew Lane and Dr. Naveen Pemmaraju discuss the unmet needs for patients with BPDCN and the potential impact of tagraxofusp (SL-401), a novel targeted therapy directed to the interleukin-3 receptor-a(CD123), for improving the clinical outcomes for this aggressive hematological tumor type.
Watch internationally renowned breast cancer clinicians discussing the latest data from the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5, and what they may mean for clinical practice.
Watch internationally renowned clinical expert, Professor Angelo Di Leo, discuss key data in advanced breast cancer presented at the 2018 American Association for Cancer Research (AACR) Annual Meeting, Chicago, USA.
This educationFEATURE on relapsed/refractory multiple myeloma (RRMM) should provide a concise overview of the promising outcomes associated with selinexor, the first-in-class, orally bioavailable, Selective Inhibitor of Nuclear Export (SINE) compound.
